Pasithea Therapeutics Corp.: 5%+ holders

As of November 10, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Pasithea Therapeutics Corp. The largest reported stake is Coastlands Capital LP's, at 11.48%. 17 filings are on record since August 14, 2025 (Schedule 13G/A, July 1, 2026).

Funicular Funds, LP also filed stake reports on 10 other companies ↓

Sell to companies like Pasithea Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-06 · Reporting person: Opaleye Management Inc. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-06
• Filing 2026-08-14 · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 9,286,738 · Shared voting: 0 · Sole dispositive: 9,286,738 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-07-31 · Holder: Opaleye Management Inc. · Percent: 6.14% · SCHEDULE 13G/A
• Filing 2026-07-01 · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 3,835,035 · Sole dispositive: 0 · Shared dispositive: 3,835,035 · SCHEDULE 13G/A, 2026-07-01
• Filing 2026-06-23 · Reporting person: Stonepine Capital Management, LLC · Sole voting: 0 · Shared voting: 1,952,550 · Sole dispositive: 0 · Shared dispositive: 1,952,550 · SCHEDULE 13G, 2026-06-23

Pasithea Therapeutics Corp. has 17 Schedule 13D or 13G filings on record since 2025-08-14. 8 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Pasithea Therapeutics Corp. and the warning signs.

See Pasithea Therapeutics Corp.'s free Snapshot Watch Pasithea Therapeutics Corp.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Pasithea Therapeutics Corp. and the records around it.

Pasithea Therapeutics Corp. elsewhere on the record

• Who owns it

Companies that share a holder

• Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
• Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Q32 Bio Inc. (Nov 2026)
• Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)

Want the whole picture on Pasithea Therapeutics Corp.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Pasithea Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Pasithea Therapeutics Corp. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   18 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Pasithea Therapeutics Corp. by CUSIP 70261F202 and gives its principal executive office as 830 Winter Street, Waltham, MA 02451 (SCHEDULE 13G/A, 2026-11-06).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Pasithea Therapeutics Corp.

Who owns Pasithea Therapeutics Corp.?

On this page, 8 holders' latest ownership filings report 5% or more of Pasithea Therapeutics Corp.: Coastlands Capital LP (11.48%, Schedule 13G/A, filed 2026-07-01), Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), Janus Henderson Group Plc (9.99%, Schedule 13G, filed 2025-12-08), Adage Capital Management, L.P. (9.99%, Schedule 13G, filed 2026-02-12) and Squadron Master Fund LP (9.9%, Schedule 13G/A, filed 2026-02-17); 3 more are listed above.

Who are the largest shareholders of Pasithea Therapeutics Corp.?

By the share each holder's latest filing reports, the largest holders of Pasithea Therapeutics Corp. on this page are Coastlands Capital LP (11.48%), Vivo Opportunity Fund Holdings, L.P. (9.99%) and Janus Henderson Group Plc (9.99%).

When did Coastlands Capital LP buy into Pasithea Therapeutics Corp.?

The filings give report dates, not purchase dates. The earliest filing from Coastlands Capital LP on this page is the Schedule 13G, filed 2026-02-27, reporting 9.99%; its latest, Schedule 13G/A filed 2026-07-01, reports 11.48%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Pasithea Therapeutics Corp.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Pasithea Therapeutics Corp.. With no account yet, you sign up free and land on the result.

• Get an alert when Pasithea Therapeutics Corp. is mentioned again
• Find former Pasithea Therapeutics Corp. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes